Course Objectives
Upon completion of this course, participants should be able to:
- Understand new evidence for detailing the pathophysiology in nonexudative age-related macular degeneration.
- Examine new evidence for predicting disease progression in nonexudative age-related macular degeneration.
- Evaluate the benefits and limitations of different imaging and visual function technologies in the diagnosis and clinical management of macular and retinal diseases.
- Incorporate the latest advances in artificial intelligence for the diagnosis and management of retinal diseases.
- Evaluate emerging therapies for the treatment of late nonexudative age-related macular degeneration and review the real-world outcomes following the use of complement inhibitors in clinical practice to better understand the population most likely to benefit from these drugs.
- Evaluate therapies targeting novel disease pathways being investigated in early-stage clinical trials for nonexudative age-related macular degeneration.
- Provide an update on anti-VEGF therapies recently approved and currently in development.
- Appreciate the next generation of therapies for exudative ocular diseases.
- Evaluate emerging therapies for the treatment of inherited retinal degenerations.